- Home
- TD vs GILD Comparison
TD vs GILD Comparison
Compare TD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TD | GILD |
|---|---|---|
| Founded | 1855 | 1987 |
| Country | Canada | United States |
| Employees | 70000 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8B | 173.9B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | TD | GILD |
|---|---|---|
| Price | $105.33 | $137.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | $120.00 | ★ $148.39 |
| AVG Volume (30 Days) | 2.6M | ★ 4.7M |
| Earning Date | 05-21-2026 | 04-24-2026 |
| Dividend Yield | ★ 2.96% | 2.37% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | N/A | $4.68 |
| Revenue Next Year | $4.48 | $6.04 |
| P/E Ratio | ★ $11.65 | $20.43 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $60.47 | $95.30 |
| 52 Week High | $104.44 | $157.29 |
Technical Indicators
Market Signals| Indicator | TD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 76.84 | 42.75 |
| Support Level | $92.13 | $133.89 |
| Resistance Level | N/A | $142.33 |
| Average True Range (ATR) | 1.39 | 3.25 |
| MACD | 1.07 | 0.09 |
| Stochastic Oscillator | 97.38 | 41.30 |
Price Performance
Historical ComparisonAbout TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).